Compare Core Scientific Inc (CORZ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Novartis AG — how do they compare? Core Scientific Inc trades at $15.21 (market cap $4.94B), while Novartis AG trades at $143.53 (market cap $268.57B). The key difference: Novartis AG is far larger — about 54.4× Core Scientific Inc's market cap, and Novartis AG pays a 3.31% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Novartis AG for 82 Days on average.
| CORZ | NVS | |
|---|---|---|
Market Cap | $4.94B | $268.57B |
Volume | 15,630,800 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $29.16 | $168.62 |
52-Week Low | $13.57 | $121.80 |
Typical Hold Time | 20 Days | 82 Days |
Enterprise Value | $7.46B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORZ trades at $15.94, down 4.44% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $288.62 million in 2025, with a negative net income margin of -324.9% in 2026. Recent news highlights its pivot to AI data center hosting and executive appointments, while analyst consensus remains strongly bullish with an 86.36% buy rating.
The outlook is mixed: strong analyst support and AI infrastructure growth offer upside potential, but persistent losses, high cash burn, and competitive pressures pose significant risks. Investors face volatility from execution challenges in the capital-intensive data center transition.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
